phenylcarbamates

Summary

Summary: Phenyl esters of carbamic acid or of N-substituted carbamic acids. Structures are similar to PHENYLUREA COMPOUNDS with a carbamate in place of the urea.

Top Publications

  1. Holeckova B, Sivikova K, Dianovsky J. Effect of N-metylcarbamate pesticide bendiocarb on cattle lymphocytes after in vitro exposure. Acta Biol Hung. 2009;60:167-75 pubmed publisher
  2. Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010;24:163-76 pubmed publisher
    ..g. health status and co-morbidities) associated with a complex disease such as AD in elderly people...
  3. Alva G, Grossberg G, Schmitt F, Meng X, Olin J. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Int J Geriatr Psychiatry. 2011;26:356-63 pubmed publisher
    ..The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items...
  4. Wattmo C, Wallin A, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist. 2011;51:17-27 pubmed publisher
  5. Kumar P, Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol. 2009;615:91-101 pubmed publisher
    ..The results show that rivastigmine could be used as an effective therapeutic agent in the management of Huntington's disease and related conditions...
  6. Kim H, Park S, Choi Y, Kang J, Joo H, Moon W, et al. Excessive O-GlcNAcylation of proteins suppresses spontaneous cardiogenesis in ES cells. FEBS Lett. 2009;583:2474-8 pubmed publisher
    ..These results suggest that excessive O-GlcNAcylation impairs cardiac cell differentiation in ES cells...
  7. Yu Q, Holloway H, Luo W, Lahiri D, Brossi A, Greig N. Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010;18:4687-93 pubmed publisher
    ..An extended duration of cholinesterase inhibition was determined in rodent, making them of potential interest as long-acting agents for myasthenia gravis...
  8. Grossberg G, Olin J, Somogyi M, Meng X. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. Int J Clin Pract. 2011;65:465-71 pubmed publisher
    ..The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch...
  9. Padonou G, Sezonlin M, Ossè R, Aizoun N, Oké Agbo F, Oussou O, et al. Impact of three years of large scale Indoor Residual Spraying (IRS) and Insecticide Treated Nets (ITNs) interventions on insecticide resistance in Anopheles gambiae s.l. in Benin. Parasit Vectors. 2012;5:72 pubmed publisher
    ..We assessed the impact of this campaign on phenotypic resistance, kdr (knock-down resistance) and ace-1(R) (insensitive acetylcholinesterase) mutations...

More Information

Publications62

  1. Jones C, Sanou A, Guelbeogo W, Sagnon N, Johnson P, Ranson H. Aging partially restores the efficacy of malaria vector control in insecticide-resistant populations of Anopheles gambiae s.l. from Burkina Faso. Malar J. 2012;11:24 pubmed publisher
    ..In this study, LLINs and IRS were tested against young (three to five days) and old (17-19 days) pyrethroid resistant Anopheles gambiae s.l. from Burkina Faso...
  2. Degim Z, Mutlu N, Yilmaz S, Essiz D, Nacar A. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie. 2010;65:32-40 pubmed
    ..The highest value of AChE inhibition was observed for rivastigmine and sodium taurocholate liposomes. The histological investigations and observations also supported these results...
  3. Cummings J, Froelich L, Black S, Bakchine S, Bellelli G, Molinuevo J, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:341-53 pubmed publisher
    ..5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses...
  4. Hatoum H, Thomas S, Lin S, Lane R, Bullock R. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil. J Med Econ. 2009;12:98-103 pubmed publisher
    ..To quantify the impact of activities of daily living (ADL) scores on the risk of nursing home placement (NHP) in Alzheimer's disease (AD) patients...
  5. Ngoh G, Facundo H, Hamid T, Dillmann W, Zachara N, Jones S. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res. 2009;104:41-9 pubmed publisher
    ..Moreover, such results support a renewed approach to the contribution of metabolism and metabolic signaling to the determination of cell fate...
  6. Bailey J, Lahiri D. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease. J Neurochem. 2010;112:843-53 pubmed publisher
  7. Wattmo C, Wallin A, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011;25:63-72 pubmed publisher
    ..AD severity at baseline is a key factor in obtaining reliable clinical prognoses of the long-term ADL ability. The dosage of ChEI treatment could possibly lead to a different functional outcome...
  8. Akogbeto M, Padonou G, Bankole H, Gazard D, Gbedjissi G. Dramatic decrease in malaria transmission after large-scale indoor residual spraying with bendiocarb in Benin, an area of high resistance of Anopheles gambiae to pyrethroids. Am J Trop Med Hyg. 2011;85:586-93 pubmed publisher
    ..Bendiocarb was found to be a good alternative insecticide for IRS in Benin, in areas where An. gambiae has developed high resistance to pyrethroids...
  9. Akogbeto M, Padonou G, Gbenou D, Irish S, Yadouleton A. Bendiocarb, a potential alternative against pyrethroid resistant Anopheles gambiae in Benin, West Africa. Malar J. 2010;9:204 pubmed publisher
    ..The goal of this study was to evaluate under field conditions the efficacy of a carbamate (bendiocarb) and an organophosphate (fenitrothion) against pyrethroid-resistant An. gambiae s.s...
  10. Mutlu N, Değim Z, Yilmaz S, Essiz D, Nacar A. New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm. 2011;37:775-89 pubmed publisher
    ..Histological observations of the mice' brains were performed under transmission electron microscope (TEM). The histological results were also indicated and supported all these findings...
  11. Grossberg G, Schmitt F, Meng X, Tekin S, Olin J. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25:627-33 pubmed publisher
    ..Rivastigmine patch was associated with improvements on the memory, praxis, and language domains of cognition in patients with mild-to-moderate AD...
  12. Farlow M, Cummings J, Olin J, Meng X. Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25:347-52 pubmed publisher
    ..Evaluation of ADAS-cog domain scores provides insight into test items most likely to respond to treatment...
  13. Bailey J, Ray B, Greig N, Lahiri D. Rivastigmine lowers A? and increases sAPP? levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS ONE. 2011;6:e21954 pubmed publisher
    ..Taken together, rivastigmine treatment enhances neuronal sAPP and shifts APP processing toward the ?-secretase pathway in degenerating neuronal cultures, which mirrors the trend of synaptic proteins, and metabolic activity...
  14. Farlow M, Grossberg G, Gauthier S, Meng X, Olin J. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Curr Med Res Opin. 2010;26:2441-7 pubmed publisher
    ..Earlier studies have demonstrated the efficacy of rivastigmine in severe Alzheimer's disease (AD), and supported the use of a higher dose patch in AD...
  15. Nagy T, Balasa A, Frank D, Rab A, Rideg O, Kotek G, et al. O-GlcNAc modification of proteins affects volume regulation in Jurkat cells. Eur Biophys J. 2010;39:1207-17 pubmed publisher
    ..In conclusion, we demonstrate for the first time that protein O-GlcNAc could modulate cell volume regulation...
  16. Zhang W, Xu Z, Cui Y, Wang H, Song M, Li J, et al. Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine. J Neural Transm (Vienna). 2009;116:1643-9 pubmed publisher
    ..25 mg/kg). These findings provide an insight into the feasibility of combined therapy with cholinesterase inhibitors and peripheral cholinoceptor antagonists for the treatment of AD...
  17. Ranson H, Abdallah H, Badolo A, Guelbeogo W, Kerah Hinzoumbé C, Yangalbé Kalnoné E, et al. Insecticide resistance in Anopheles gambiae: data from the first year of a multi-country study highlight the extent of the problem. Malar J. 2009;8:299 pubmed publisher
    ..The current extent and distribution of this resistance in many parts of the continent is unknown and yet such information is essential for the planning of effective malaria control interventions...
  18. Joshi S, Chavhan S, Sawant K. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76:189-99 pubmed publisher
    ..This indicates rapid and higher extent of transport of RT into the mice brain and thus shows the suitability of both NPs as potential carriers for providing sustained brain delivery of RT...
  19. Yanagisawa M, Yu R. O-linked beta-N-acetylglucosaminylation in mouse embryonic neural precursor cells. J Neurosci Res. 2009;87:3535-45 pubmed publisher
    ..Furthermore, in NECs, we identified an O-GlcNAc-modified protein, Sp1 transcription factor. Our study is the first to evaluate expression and functions of O-GlcNAc in NECs...
  20. Farlow M, Grossberg G, Meng X, Olin J, Somogyi M. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. Int J Geriatr Psychiatry. 2011;26:1236-43 pubmed publisher
    ..This exploratory, hypothesis-forming analysis assessed response to rivastigmine according to severity of dementia at baseline...
  21. Ho C, Popat S, Liu T, Tsai K, Ho M, Chen W, et al. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors. ACS Chem Biol. 2010;5:489-97 pubmed publisher
    ..5 x 10(5) times more selective for Hex B than for a similar human enzyme O-GlcNAcase. These glycosidase inhibitors were shown to modulate intracellular levels of glycolipids, including ganglioside-GM2 and asialoganglioside-GM2...
  22. Salem M, El Kosasy A, El Bardicy M, Abd El Rahman M. Spectrophotometric and spectrodensitometric methods for the determination of rivastigmine hydrogen tartrate in presence of its degradation product. Drug Test Anal. 2010;2:225-33 pubmed publisher
    ..The proposed methods have been successfully applied to the analysis of RIV in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with reference method...
  23. Arumugam K, Subramanian G, Mallayasamy S, Averineni R, Reddy M, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008;58:287-97 pubmed publisher
    ..Delivering rivastigmine liposomes through the intranasal route for the treatment of Alzheimer's disease might be a new approach to the management of this condition...
  24. Winblad B, Machado J. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv. 2008;5:1377-86 pubmed
    ..The apparent success of rivastigmine patch, in terms of clinical utility and patient acceptability, suggests that it may mark the next generation of dementia treatment...
  25. Matthews J, Acevedo Duncan M, Potter R. Selective decrease of membrane-associated PKC-alpha and PKC-epsilon in response to elevated intracellular O-GlcNAc levels in transformed human glial cells. Biochim Biophys Acta. 2005;1743:305-15 pubmed
    ..In addition, none of the three compounds affected membrane levels of PKC-iota. Altogether, these results demonstrate a novel link between increased levels of the O-GlcNAc modification and the regulation of specific PKC isoforms...
  26. Aguglia E, Onor M, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. Curr Med Res Opin. 2004;20:1747-52 pubmed
    ..We analysed the effects of donepezil, rivastigmine and galantamine, prescribed for the treatment of Alzheimer disease in a real-world setting in Italy...
  27. Park S, Ryu J, Lee W. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes. Exp Mol Med. 2005;37:220-9 pubmed
  28. Thompson S, Lanctot K, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf. 2004;3:425-40 pubmed
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  29. Blennow K, de Leon M, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403 pubmed
    ..This seminar reviews the key aspects of the disease, including epidemiology, genetics, pathogenesis, diagnosis, and treatment, as well as recent developments and controversies...
  30. Matthews J, Belof J, Acevedo Duncan M, Potter R. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells. Mol Cell Biochem. 2007;298:109-23 pubmed
    ..The mechanism by which STZ increases Akt phosphorylation, however, remains unknown...
  31. Xing D, Feng W, Nöt L, Miller A, Zhang Y, Chen Y, et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol. 2008;295:H335-42 pubmed publisher
    ..Augmenting O-GlcNAc modification of proteins in the vasculature may represent a novel anti-inflammatory and vasoprotective mechanism...
  32. Feldman H, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007;6:501-12 pubmed
    ..To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline...
  33. Starr J. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease. J Am Geriatr Soc. 2007;55:800-1 pubmed
  34. Maharaj R, Casimiro S, Mthembu S, Sharp B. The residual life of bendiocarb: a field-based evaluation from Mozambique. J Med Entomol. 2004;41:130-2 pubmed
    ..The different types of surfaces sprayed did not affect the residual life of bendiocarb. Therefore, to achieve effective control in a malaria-endemic area such as southern Mozambique, two spray rounds per annum are necessary...
  35. Arias E, Kim J, Cartee G. Prolonged incubation in PUGNAc results in increased protein O-Linked glycosylation and insulin resistance in rat skeletal muscle. Diabetes. 2004;53:921-30 pubmed
  36. Ritchie C, Ames D, Clayton T, Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry. 2004;12:358-69 pubmed
    ..However, both galantamine and rivastigmine were associated with a greater risk of trial dropout than placebo, especially at higher dosing levels...
  37. Liu J, Marchase R, Chatham J. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007;293:H1391-9 pubmed
  38. Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, et al. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness. Clin Ther. 2002;24:862-86; discussion 837 pubmed
    ..Various drugs have been approved for the treatment of Alzheimer's disease (AD) in the United States and Canada, including donepezil and rivastigmine, although questions remain as to their efficacy, effectiveness, and long-term benefits...
  39. Finkel S. Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004;26:980-90 pubmed
    ..Regulatory studies of rivastigmine in AD were not designed to evaluate effects on BPSD, but further investigation of rivastigmine in AD was prompted by later studies demonstrating behavioral benefits in other types of dementia...
  40. Blesa R, Ballard C, Orgogozo J, Lane R, Thomas S. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007;69:S23-8 pubmed
    ..Preference for the patch may indicate reduced caregiver stress, substantiated by greater satisfaction and less interference with daily life. These benefits may lead to improved compliance...
  41. Zhao Q, Tang X. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol. 2002;455:101-7 pubmed
    ..These results suggest that the use of acetylcholinesterase inhibitors in treatment of Alzheimer's disease must consider both form-specific and region-specific characteristics of acetylcholinesterase inhibition...
  42. Andin J, Enz A, Gentsch C, Marcusson J. Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression. Dement Geriatr Cogn Disord. 2005;19:18-23 pubmed
    ..These results provide the first evidence that the glutamatergic system is modulated following acetylcholinesterase inhibition by rivastigmine, a finding, which is likely to be of importance for the clinical effects...
  43. Wilkinson D, Passmore A, Bullock R, Hopker S, Smith R, Potocnik F, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 2002;56:441-6 pubmed
    ..Thus, using the recommended dosing schedules, donepezil was better tolerated with fewer discontinuations due to AEs, and both agents improved cognition to a similar extent...
  44. Kaduszkiewicz H, Zimmermann T, Beck Bornholdt H, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005;331:321-7 pubmed
    ..Three cholinesterase inhibitors are currently recommended: donepezil, rivastigmine, and galantamine. This review assessed the scientific evidence for the recommendation of these agents...
  45. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21:1317-27 pubmed
  46. Amenta F, Tayebati S, Vitali D, Di Tullio M. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev. 2006;127:173-9 pubmed
  47. Gauthier S, Juby A, Morelli L, Rehel B, Schecter R. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin. 2006;22:2251-65 pubmed
  48. Cummings J, Lefèvre G, Small G, Appel Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology. 2007;69:S10-3 pubmed
    ..The potential of a patch to improve the tolerability of rivastigmine (e.g., nausea and vomiting) while permitting similar exposure to the highest doses of capsules may, in turn, lead to improved efficacy and compliance...
  49. Small G, Kaufer D, Mendiondo M, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005;59:473-7 pubmed
    ..3 (+/-4.9). Projected mean scores in model-based untreated patients declined below 10 points on the MMSE at about 3 years, while the mean MMSE score of patients who remained on rivastigmine stayed above 10 points for 5 years...
  50. Raschetti R, Maggini M, Sorrentino G, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol. 2005;61:361-8 pubmed
  51. Farlow M. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc. 2006;81:1350-8 pubmed
    ..These data suggest that antidementia drugs currently used for treatment of AD should be considered for treatment of VaD as well...
  52. Whitworth G, Macauley M, Stubbs K, Dennis R, Taylor E, Davies G, et al. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J Am Chem Soc. 2007;129:635-44 pubmed publisher
  53. Lefevre G, Sedek G, Jhee S, Leibowitz M, Huang H, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. 2008;83:106-14 pubmed
    ..Average exposure with the 10 cm2 patch was comparable to the highest capsule dose (6 mg Q12H, i.e., 12 mg/day)...